Skip to main content
Find more clinical trials

LY3303560 Study

Start: April 2016
End: July 10, 2018
Enrollment: 90

What Is This Study About?

This study will evaluate the safety and tolerability of the experimental drug LY3303560, Participants may be healthy or have mild cognitive impairment (MCI) due to Alzheimer's disease or early-to-moderate Alzheimer's.

Do I Qualify To Participate in This Study?

Minimum Age: 30 Years

Maximum Age: N/A

Must have:

  • Overtly healthy
  • Non-childbearing potential

Alzheimer's and MCI Participants

  • At least 50 years old
  • Meet diagnostic criteria consistent with either MCI due to Alzheimer's or mild-to moderate Alzheimer's
  • Positive florbetapir positron emission tomography (PET) scan

Must NOT have:

  • Known allergies to LY3303560, related compounds, or any components of the formulation
  • History of significant atopy (hereditary disorder marked by tendency to develop immediate allergic reactions to substances)
  • Increased risk of seizures
  • For Alzheimer's participants, evidence of macrohemorrhage or greater than 4 microhemorrhage seen by magnetic resonance imaging

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Eli Lilly and Company

Source: ClinicalTrials.gov ID: NCT02754830